- Home
- PCM vs UNCY Comparison
PCM vs UNCY Comparison
Compare PCM & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCM
- UNCY
- Stock Information
- Founded
- PCM 1993
- UNCY 2016
- Country
- PCM United States
- UNCY United States
- Employees
- PCM N/A
- UNCY N/A
- Industry
- PCM Trusts Except Educational Religious and Charitable
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- PCM Finance
- UNCY Health Care
- Exchange
- PCM Nasdaq
- UNCY Nasdaq
- Market Cap
- PCM 82.0M
- UNCY 74.2M
- IPO Year
- PCM N/A
- UNCY 2021
- Fundamental
- Price
- PCM $6.33
- UNCY $4.80
- Analyst Decision
- PCM
- UNCY Strong Buy
- Analyst Count
- PCM 0
- UNCY 5
- Target Price
- PCM N/A
- UNCY $55.20
- AVG Volume (30 Days)
- PCM 29.1K
- UNCY 405.7K
- Earning Date
- PCM 01-01-0001
- UNCY 11-12-2025
- Dividend Yield
- PCM 11.68%
- UNCY N/A
- EPS Growth
- PCM N/A
- UNCY N/A
- EPS
- PCM N/A
- UNCY N/A
- Revenue
- PCM N/A
- UNCY N/A
- Revenue This Year
- PCM N/A
- UNCY N/A
- Revenue Next Year
- PCM N/A
- UNCY $19,912.34
- P/E Ratio
- PCM N/A
- UNCY N/A
- Revenue Growth
- PCM N/A
- UNCY N/A
- 52 Week Low
- PCM $6.88
- UNCY $3.71
- 52 Week High
- PCM $10.20
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- PCM 33.26
- UNCY 53.34
- Support Level
- PCM $6.28
- UNCY $4.62
- Resistance Level
- PCM $6.41
- UNCY $5.39
- Average True Range (ATR)
- PCM 0.14
- UNCY 0.33
- MACD
- PCM -0.04
- UNCY -0.01
- Stochastic Oscillator
- PCM 22.10
- UNCY 44.58
About PCM PCM Fund Inc.
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.